1052 related articles for article (PubMed ID: 33171772)
1. Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease.
Silvestro S; Schepici G; Bramanti P; Mazzon E
Molecules; 2020 Nov; 25(21):. PubMed ID: 33171772
[TBL] [Abstract][Full Text] [Related]
2. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C
Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol induces antidepressant and anxiolytic-like effects in experimental type-1 diabetic animals by multiple sites of action.
Chaves YC; Genaro K; Crippa JA; da Cunha JM; Zanoveli JM
Metab Brain Dis; 2021 Apr; 36(4):639-652. PubMed ID: 33464458
[TBL] [Abstract][Full Text] [Related]
4. A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD).
Peng J; Fan M; An C; Ni F; Huang W; Luo J
Basic Clin Pharmacol Toxicol; 2022 Apr; 130(4):439-456. PubMed ID: 35083862
[TBL] [Abstract][Full Text] [Related]
5. Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research.
Melas PA; Scherma M; Fratta W; Cifani C; Fadda P
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668469
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotection Following Concussion: The Potential Role for Cannabidiol.
Singh J; Neary JP
Can J Neurol Sci; 2020 May; 47(3):289-300. PubMed ID: 32029015
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors.
Linge R; Jiménez-Sánchez L; Campa L; Pilar-Cuéllar F; Vidal R; Pazos A; Adell A; Díaz Á
Neuropharmacology; 2016 Apr; 103():16-26. PubMed ID: 26711860
[TBL] [Abstract][Full Text] [Related]
8. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.
Silvestro S; Mammana S; Cavalli E; Bramanti P; Mazzon E
Molecules; 2019 Apr; 24(8):. PubMed ID: 31013866
[TBL] [Abstract][Full Text] [Related]
9. Cannabis sativa: Much more beyond Δ
Alves P; Amaral C; Teixeira N; Correia-da-Silva G
Pharmacol Res; 2020 Jul; 157():104822. PubMed ID: 32335286
[TBL] [Abstract][Full Text] [Related]
10. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.
Campos AC; Moreira FA; Gomes FV; Del Bel EA; Guimarães FS
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3364-78. PubMed ID: 23108553
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.
Ward SJ; McAllister SD; Kawamura R; Murase R; Neelakantan H; Walker EA
Br J Pharmacol; 2014 Feb; 171(3):636-45. PubMed ID: 24117398
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors.
Pazos MR; Mohammed N; Lafuente H; Santos M; Martínez-Pinilla E; Moreno E; Valdizan E; Romero J; Pazos A; Franco R; Hillard CJ; Alvarez FJ; Martínez-Orgado J
Neuropharmacology; 2013 Aug; 71():282-91. PubMed ID: 23587650
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol Exerts Anticonvulsant Effects Alone and in Combination with Δ
Javadzadeh Y; Santos A; Aquilino MS; Mylvaganam S; Urban K; Carlen PL
Cells; 2024 Mar; 13(6):. PubMed ID: 38534310
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action.
Ożarowski M; Karpiński TM; Zielińska A; Souto EB; Wielgus K
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919010
[TBL] [Abstract][Full Text] [Related]
15. Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals.
Galaj E; Xi ZX
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374481
[TBL] [Abstract][Full Text] [Related]
16. Molecular Targets of Cannabidiol in Neurological Disorders.
Ibeas Bih C; Chen T; Nunn AV; Bazelot M; Dallas M; Whalley BJ
Neurotherapeutics; 2015 Oct; 12(4):699-730. PubMed ID: 26264914
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.
Sagredo O; Ramos JA; Decio A; Mechoulam R; Fernández-Ruiz J
Eur J Neurosci; 2007 Aug; 26(4):843-51. PubMed ID: 17672854
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Junior NCF; Dos-Santos-Pereira M; Guimarães FS; Del Bel E
Neurotox Res; 2020 Jan; 37(1):12-29. PubMed ID: 31637586
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders.
de Fátima Dos Santos Sampaio M; de Paiva YB; Sampaio TB; Pereira MG; Coimbra NC
Basic Clin Pharmacol Toxicol; 2024 May; 134(5):574-601. PubMed ID: 38477419
[TBL] [Abstract][Full Text] [Related]
20. Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments.
Mori MA; Meyer E; da Silva FF; Milani H; Guimarães FS; Oliveira RMW
Eur J Neurosci; 2021 Mar; 53(6):1738-1751. PubMed ID: 33522084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
